Elisa is a Partner of Syncona Investment Management Limited. She is a Director on the Board of Quell Therapeutics, Beacon Therapeutics and Forcefield Therapeutics and was previously on the Board of former portfolio companies Blue Earth Diagnostics and Neogene, and Achilles Therapeutics. She was closely involved in the foundation of Quell, Blue Earth, Achilles and Beacon including their operational and strategic set-up. Previously, she was a Senior Associate at Michel Dyens & Co. working on transactions covering the healthcare space, and a member of the Life Science team at L.E.K. Consulting based in London. While at L.E.K. she worked on projects for biotech, pharma and private equity clients. Elisa has a PhD in Molecular Biology from Imperial College and an MBA from London Business School.

Stephanie Murtagh is the Co-Founder of Cavenagh Health, an executive search firm specialising in the Life Sciences sector. She partners with early-stage and scaling ventures to build leadership teams that drive innovation and long-term value creation. With over 20 years of experience at the intersection of entrepreneurship, investment, and talent strategy, Stephanie is a trusted advisor to founders and investors across the global Biotech, TechBio, MedTech, and Digital Health ecosystems. Since 2010, she has focused exclusively with early-stage companies, combining deep sector knowledge with a sharp instinct for identifying high-impact opportunities. Her work spans investment strategy and portfolio development, helping ventures align the right leadership with the right capital to accelerate growth. Stephanie plays an active, hands-on role in supporting high-growth companies across Europe and North America. She is widely recognised for her ability to connect early-stage teams with the talent, networks, and strategic clarity needed to scale effectively. Her international perspective and strong ties to the global investment community make her a valuable partner to both emerging founders and established venture firms.

Emma is a Senior Investment Manager in the Direct Investments team at the British Business Bank, where she leads investments into stand-out companies across the UK life sciences sector at Series A+. Emma joined at the inception of the organisations Direct Investment strategy in 2021 and has built a portfolio spanning first-in-class therapies, novel therapeutic modalities and technologies driving efficiencies in both the life sciences industry and healthcare system. Previously, Emma spent three years investing in a broad array of life sciences companies for the Greater Manchester and Cheshire Life Sciences Fund managed by Catapult Ventures, and has an academic background in Neuroscience

Liz has more than 23 years of experience in the life science and healthcare industry, either as a venture investor, director or an operating executive. She focuses on shaping and building early-stage life science opportunities into successful companies and investments. Liz is a General Partner of Epidarex Capital, a majority women owned and led venture capital firm which finds, invests in, and builds early-stage breakthrough life sciences companies in emerging hubs. In her role at Epidarex she is responsible for all aspects of the firm from sourcing and leading investments, managing the portfolio to developing the strategy for the firm’s future growth. Prior to joining Epidarex, Liz was Head of Business Development and part of the management team at Chroma Therapeutics Ltd where she established several major company-building alliances. Liz is a former executive with the life science venture capital team at the Investments Division of The Wellcome Trust. She is also a former member of the life Science team at Atlas Ventures, London. Liz has held numerous directorships throughout her career including Dunad, Nodthera, Exeed, Mironid, EM Imaging, Macomics, AdoRx Therapeutics, Enterprise Therapeutics and Kynos. Liz holds a B.Sc. (Hons) in Biochemistry (1st class) from the University College Cork, and a Ph.D. from the Imperial Cancer Research Fund.

Nick Ross is the Co-Founder of Cavenagh Health, a specialist executive search and talent advisory firm focused on building leadership teams for early-stage biotech, medtech, and healthtech ventures across the UK, Europe, and the US. With a track record of partnering with some of the most innovative life science companies, Nick plays a pivotal role in aligning talent strategy with venture growth and long-term value creation. Beyond search, Nick is a trusted strategic advisor and emerging investor, working closely with founders and boards to guide capital deployment, talent planning, and organisational design. His insight is regularly sought by venture funds and accelerators to support portfolio companies as they transition from scientific promise to commercial success. At the core of Nick's work is a mission to connect visionary talent with transformative science, ensuring that groundbreaking ideas translate into real-world health solutions.

Lene Gerlach has 25 years of experience in the life science industry. Over the past decade, she has been deeply involved in venture capital, having financed more than 35 companies, led follow-up capital rounds, and executed exits. Lene comes from a Partner position in Eir Ventures. She has extensive board experience, having served as Chairperson for 18 companies.

Shelley Margetson joined V-Bio Ventures in December 2020 as Managing Partner. Prior to joining V-Bio Ventures, Shelley spent over 20 years in executive roles in both finance and business, across various European biotechnology companies. As CFO of Merus (MRUS) she managed the Initial Public Offering on the Nasdaq in May 2016 and as CEO of Gadeta she closed a ‘build to buy’ deal with Kite/Gilead. Shelley has managed funding rounds, business exits and negotiated international business transactions, spanning three continents. She has a finance/business background, holds a BA in business economics and is a member of the Chartered Institute of Management Accountants.